NICE backs Lilly’s Emgality for migraine, adding pressure on...

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve th

Novartis’ Aimovig tops topiramate in migraine face-off

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head tri

After rejection, NICE agrees to look again at migraine drug ...

Blow to Novartis as NICE rejects migraine drug Aimovig again

Cancer update buoys Amgen despite Q2 sales fall

Scotland backs Aimovig for migraine after NICE says no

People suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig if they fail other therapies, according to the country’s cost-effectiveness